A

Acarix AB
F:7AC

Watchlist Manager
Acarix AB
F:7AC
Watchlist
Price: 0.0161 EUR -0.62% Market Closed
Market Cap: €15.7m

Wall St Price Targets

7AC Price Targets Summary
Acarix AB

Wall Street analysts forecast 7AC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 7AC is 0.0289 EUR with a low forecast of 0.0286 EUR and a high forecast of 0.0297 EUR.

Lowest Forecast
Price Target
0.0286 EUR
78% Upside
Average Forecast
Price Target
0.0289 EUR
79% Upside
Highest Forecast
Price Target
0.0297 EUR
85% Upside
Acarix AB Competitors:
Price Targets
PHUN
Phunware Inc
207% Upside
PMVP
PMV Pharmaceuticals Inc
288% Upside
GWH
ESS Tech Inc
197% Upside
XPEL
Xpel Inc
24% Upside

Revenue
Forecast

N/A
Past Growth
304% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss
N/A
Past Growth
304% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss

The compound annual growth rate for Revenue over the next 2 years is 304%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-87%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-87%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 7AC's stock price target?
Price Target
0.0289 EUR

According to Wall Street analysts, the average 1-year price target for 7AC is 0.0289 EUR with a low forecast of 0.0286 EUR and a high forecast of 0.0297 EUR.

What is the Revenue forecast for Acarix AB?
Projected CAGR
304%

The compound annual growth rate for Revenue over the next 2 years is 304%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett